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Background: Noninvasive markers of liver fibrosis have not been extensively studied in patients with chronic
hepatitis B virus (HBV) infection. Our aim was to evaluate the capacity of FibroSURE, one of the two noninvasive
fibrosis indices commercially available in the United States, to identify HBV infected patients with moderate to
severe fibrosis.
Methods: Forty-five patients who underwent liver biopsy at a single tertiary care center were prospectively enrolled
and had FibroSURE performed within an average interval of 11 days of the biopsy.
Results: Of the 45 patients, 40% were Asian, 40% were African American, and 13% were Caucasian; 27% were co-
infected with HIV and 67% had no or mild fibrosis. We found FibroSURE to have moderate capacity to discriminate
between patients with moderate to high fibrosis and those with no to mild fibrosis (area under receiver operating
characteristic [AUROC] curve = 0.77; 95% confidence interval [CI] [0.61, 0.92]). When we combined the fibrosis score
determined by FibroSURE with aspartate aminotransferase (AST) measurements and HIV co-infection status, the
discriminatory ability significantly improved reaching an AUROC of 0.90 (95% CI [0.80, 1.00]). FibroSURE also had a
good ability to differentiate patients with no or mild from those with moderate to high inflammation (AUROC = 0.83;
95% CI [0.71, 0.95]).
Conclusions: FibroSURE in combination with AST levels has an excellent capacity to identify moderate to high fibrosis
stages in chronic HBV-infected patients. These data suggest that FibroSURE may be a useful substitute for liver biopsy
in chronic HBV infection.
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Chronic hepatitis B virus (HBV) infection affects 350
to 400 million people worldwide [1,2]. The disease can
progress to cirrhosis and hepatocellular carcinoma in
approximately 15% to 40% of patients. The long-term
complications are more frequent in patients with active
viral replication as well as in those with significant intra-
hepatic inflammation and fibrosis [3]. Therefore, assess-
ment of liver pathology is very important clinically as it
identifies patients most likely to benefit from antiviral
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unless otherwise stated.Currently, the “gold standard” for the assessment of
hepatic fibrosis is liver biopsy. Liver biopsy is recom-
mended by the most recent AASLD guidelines on HBV
in order to determine the need for antiviral therapy for
those with normal liver enzymes who meet treatment cri-
teria based on the viral load [4,5]. However, the procedure
has several drawbacks including morbidity, mortality, sig-
nificant sampling error, and high cost. It is associated with
marked inter- and intra- observer/pathologist variability,
and the use of different scoring systems to assess the
degree of intrahepatic inflammation and fibrosis further
complicates comparisons between pathologists. These
limitations are important issues, particularly when patients
seek a second opinion [6]. Finally, the invasive nature of
the biopsy makes it unsuitable for serial hepatic sampling.
In an attempt to overcome these limitations, severalal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Patients characteristics
Parameter Patients (N = 45)
Mean (SD) age, years 42.4 (12.15)
Gender Male 26 (58%)
Female 19 (42%)
Ethnicity Caucasian 6 (13%)














HIV co-infected 12 (27%)
Mean ALT (U/L) (range) 53 (10–240)
Mean AST (U/L) (range) 46 (13–302)
Mean HBV DNA (IU/ml) (range) 33,476,858 (<20-200,000,000)
Positive HBeAg 19 (42%)
ALT, AST, and HBV DNA measurements were not available for one HBV-infected
patient.
Abbreviations: ALT alanine aminotransferase, AST aspartate aminotransferase,
SD standard deviation, HBV hepatitis B virus.
Zeremski et al. BMC Gastroenterology 2014, 14:118 Page 2 of 8
http://www.biomedcentral.com/1471-230X/14/118indices that incorporate parameters associated with in-
flammation or fibrogenesis, such as FibroTest/FibroSURE
[7,8], Forns’ index [9], or the aspartate aminotransferase
(AST)/platelet ratio index [10], have been proposed as non-
invasive alternatives. FibroSURE (Laboratory Corporation
of America (LabCorp), Burlington, NC) and FIBROSpect II
(Prometheus Laboratories, San Diego, CA) are the only two
commercially available noninvasive indices used in the
United States. Both of these tests have been developed and
extensively validated in patients with hepatitis C [11,12],
but their utility in hepatitis B has not been adequately
evaluated. In this study, we prospectively assessed the
performance characteristics of FibroSURE as a noninvasive
test for measuring liver inflammation and fibrosis in
patients with chronic hepatitis B infection.
Methods
Patients
All HBV-infected patients who underwent a liver biopsy
at our institution between 2005 and 2012 were prospect-
ively approached and offered participation in this study.
We enrolled 45 HBV-infected patients, 12 (26.7%) of
whom were co-infected with HIV. Patients with HCV
co-infection and other co-existing liver diseases were
excluded. The study was approved by the Weill Cornell
Medical College institutional review board and was per-
formed in accordance with the Declaration of Helsinki.
After signing an informed consent, each patient’s blood
was drawn and sent to LabCorp for performance of the
FibroSURE. Alanine aminotransferase (ALT) and AST
levels, as well as HBV DNA measurements, were
extracted from the electronic medical record and were
performed, on average, within 1 month (ALT and AST),
or within 2 months (HBV DNA), of the liver biopsy or
FibroSURE. All liver biopsies were evaluated according
to the Scheuer classification [13] by the same hepato-
pathologist (RKY).
Statistical analysis
Statistical analysis was performed using SAS (SAS Institute
Inc., Cary, NC, USA) and R (http://www.r-project.org/).
Aminotransferase levels were logarithmically transformed
for the analysis. Associations between categorical variables
were assessed through Fisher’s exact test and logistic
regression. For continuous variables, comparisons between
groups were performed using Wilcoxon rank-sum or
Kruskal-Wallis tests. Diagnostic abilities of FibroSURE
were expressed through the estimated area under the
receiver operating characteristic (AUROC) curve and by
calculation of the respective sensitivity, specificity, positive
and negative predictive values estimated for appropriate
cut-off values. The AUROC was estimated by the trapez-
oidal rule and represents the probability that a randomly
selected pair of subjects will be classified correctly. In orderto estimate the linear combination of the available vari-
ables, which detects fibrosis stage and inflammation grade,
we used logistic regression. Comparison of the ROC
curves was based on the methods described by DeLong
et al. [14]. The significance level in all tests (two-sided)
was set to 0.05.
Results
Patients’ characteristics
A total of 45 patients with chronic HBV infection, 12 of
whom were HIV/HBV co-infected, were included in this
study. Patients’ mean age was 42.4 years, 58% were male,
40% were Asian, 40% were African American, and 13%
were Caucasian (Table 1). Among the twelve HIV/HBV
co-infected patients, 83.3% were African American and
16.7% were Caucasian. Ten patients, nine of whom were
HIV co-infected, were on treatment for chronic HBV in-
fection during the time of the liver biopsy/FibroSURE.
One patient was taking Lamivudine, two were on Tenofovir,
four patients were on Truvada, and three patients, one of
whom was HBV mono-infected, were on Entecavir. Most of
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necroinflammation less than or equal to grade 1 and 67%
had stage 0–1 fibrosis. In addition, 55.6% of patients had
ALT levels that were in the normal range (0 – 45 U/L).
Only 8.9% of patients had ALT values greater than two
times the upper limit of normal.
FibroSURE test was performed an average of 11 days pre-
ceding or after the liver biopsy. However, in the majority of
patients (62%), it was performed on the same day as the
liver biopsy.
HIV/HBV co-infected patients had significantly higher fi-
brosis levels, as estimated by both liver biopsy (p = 0.0099)
and FibroSURE (p = 0.0425), compared to HBV mono-
infected patients. Although the histologic grade of intra-
hepatic necroinflammation did not differ significantly
depending upon type of infection, co-infected patients
had significantly higher FibroSURE inflammatory scores
compared to mono-infected patients (p = 0.0341). Of
note, HBV/HIV co-infected patients had significantly
higher ALT levels compared to HBV mono-infected
patients (p = 0.017).
FibroSURE as a predictor of liver fibrosis
As expected, values obtained on FibroSURE were signifi-
cantly higher in patients with moderate to severe fibrosis
(stage ≥ 2) compared to those with mild or no fibrosis
(stage ≤ 1) (p = 0.0158) (Figure 1A; Table 2). Advanced
fibrosis was also associated with HIV co-infection (p =
0.0156) and grade of inflammation (p = 0.0066). Patients
with advanced fibrosis had significantly higher ALT (p =
0.0067) and AST (p = 0.035) levels, but only based on
univariable logistic regression analysis (Table 2).
When we evaluated the ability of FibroSURE to discrim-
inate between patients with mild or no fibrosis (stage ≤ 1)
and those with moderate to severe fibrosis (stage ≥ 2), the
calculated area under the ROC curve was 0.77 (95% confi-
dence interval [CI] 0.61, 0.92). ALT and AST measure-
ments had similar discriminatory abilities (AUROC= 0.79;
95% CI: 0.65, 0.92; p = 0.8096 and AUROC= 0.76; 95% CI:
0.61, 0.90; p = 0.9064, respectively). For example, a cut-off
value of FibroSURE ≥ 0.49 resulted in sensitivity of 0.47,
specificity of 0.93, positive predictive value (PPV) of 0.78
and negative predictive value (NPV) of 0.77. However, the
combination of FibroSURE with AST and HIV co-
infection status improved its capacity to identify patients
with moderate to severe (stage ≥ 2) fibrosis. Based on lo-
gistic regression, the following linear score:
1:65þ 2:26 FibroSURE‐19:28
1 if HBV mono‐infectedf g‐1:07 log10 ASTð Þ þ 10:93
1 if HBV mono‐infectedf glog10 ASTð Þ
had AUROC of 0.90 (95% CI [0.80, 1.00]) (Figure 2A),
which was significantly better than either FibroSURE(p = 0.0156) or AST (p = 0.0450) values individually.
When we evaluated the performance characteristics of the
model, we found that a cut-off score of 0.44 or higher re-
sulted in sensitivity of 0.73, specificity of 0.97, PPV of 0.92
and NPV of 0.88. A cut-off score of −2.15 had sensitivity
of 1, specificity of 0.55, PPV of 0.54 and NPV of 1 to iden-
tify patients with moderate to high fibrosis (Figure 2B).
FibroSURE as a predictor of liver inflammation
FibroSURE inflammatory scores were significantly higher
in patients with higher intrahepatic inflammation com-
pared to those with mild or no inflammation (stage ≤ 1)
(p = 0.0003) (Figure 1B). Based on univariable logistic
regression analysis, advanced inflammation was also
associated with male gender (p = 0.0228), higher stages
of fibrosis (p = 0.0032), ALT levels (p = 0.0014), AST
levels (p = 0.0047), and HBV DNA (p = 0.0135).
FibroSURE had good ability to differentiate patients
with mild or no inflammation (grade ≤ 1) from those with
moderate to high inflammation (grade ≥ 2); AUROC =
0.83 (95% CI [0.71, 0.95]) (Figure 3A). Using a cut-off
value of 0.52 for FibroSURE inflammation score, we
obtained sensitivity of 0.38, specificity of 1, PPV of 1 and
NPV of 0.639 (Figure 3B). However, the ability of Fibro-
SURE to indicate moderate to high inflammation in chro-
nic HBV patients was not significantly higher compared
to ALT (AUROC= 0.84; 95% CI: 0.72, 0.95; p = 0.8191) or
AST (AUROC= 0.78; 95% CI: 0.65, 0.92; p = 0.4132) mea-
surements individually (Figure 3A). The addition of AST,
HBV DNA measurements, or male sex to the FibroSURE
inflammation score did not improve its discriminatory
ability. As ALT is a component of the FibroSURE score,
evaluation of the combination of ALT and inflammation
as assessed by FibroSURE would not improve the diagnos-
tic performance.
Discussion
Unlike HCV, in HBV, treatment endpoints include bio-
chemical responses, as indicated by normalization of
ALT, and histological responses, as indicated by reduced
necroinflammation and reversion of fibrosis [2]. Al-
though liver biopsy has been considered the “gold standard”
for the assessment of intrahepatic pathology, the procedure
has significant limitations including invasiveness, high cost
and poor reproducibility [6]. In the last decade, several
non-invasive indices have been developed as liver biopsy
alternatives. While indices, such as FibroSURE and Fibros-
pect, have largely been developed and validated in patients
with chronic HCV infection, their use in HBV-infected
patients has not been nearly as extensive. Given the
therapeutic importance of necroinflammatory activity and
fibrosis in HBV infection, a noninvasive index such as
FibroSURE might have an important role in the manage-
ment of the infection.
Figure 1 Boxplots illustrating the distribution of FibroSURE fibrosis scores stratified by fibrosis stage (A), and FibroSURE inflammation
scores stratified by inflammatory grade (B). The number of people in each category is listed in parenthesis adjacent to the fibrosis stage.
Please note that only seven patients had advanced fibrosis and inflammation (stages/grades 3 or 4).
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Table 2 Logistic regression analysis on moderate to severe stage of fibrosis
Stage > =2
(n = 15) n (%) or Mean (SD)
Stage < 2
(n = 30) n (%) or Mean (SD)
Univariable logistic regression Multivariable logistic regression***
Variable OR 95% CI p-value p-value
Age 46.87 (13.93) 40.17 (10.72) 1.05 0.993; 1.110 0.089
Gender, N (%) Male 11 (42.31) 15 (57.69) 2.75 0.713; 10.605 0.1418 0.0641
Female* 4 (21.05) 15 (78.95)
Race, N (%) Caucasian* 1 (16.67) 5 (83.33) 0.2845
AA 9 (50.00) 9(50.00) 5 0.483; 51.769
Asian 4 (22.22) 14 (77.78) 1.429 0.127; 16.025
Other 1 (33.33) 2 (66.67) 2.5 0.1; 62.602
Diagnosis HBV 7 (21.21) 26 (78.79) 0.135 0.031; 0.581 0.0072** 0.0156**
HIV/HBV* 8 (66.67) 4 (33.33)
Inflammation Grade > 1 12 (57.14) 9 (42.86) 9.333 2.110; 41.278 0.0032** 0.0066**
Grade < =1* 3 (12.50) 21 (87.50)
FibroSURE 0.462 (0.297) 0.212 (0.167) 3.015§ 1.426; 6.374 0.0039** 0.0158**
log10 ALT (U/L) 1.81 (0.25) 1.52 (0.28) 3.314
§ 1.393; 7.883 0.0067**
log10 AST (U/L) 1.70 (0.21) 1.51 (0.25) 2.455
§ 1.065; 5.658 0.0350**
log10 HBV DNA (IU/ml) 5.24 (2.98) 4.60 (2.39) 1.304
§ 0.674; 2.520 0.4303
*Reference group for the reported odds ratios.
**p-value < 0.05.
***Based on the best selected model.
§OR of 1 SD increase.


















Figure 2 Receiver operating characteristic (ROC) curves of the
combined model (as described in Results), FibroSURE and log10
(AST) for the detection of moderate to severe fibrosis (stage ≥ 2).
Values of the area under ROC curves for the individual variables are
indicated in parenthesis at the bottom of the image (A). Sensitivity and
specificity of the model score for a range of cut-off values (B).
Figure 3 Receiver operating characteristic (ROC) curves of the
FibroSURE inflammation score, log10(AST) and log10(ALT) for
the detection of moderate to severe inflammation (grade ≥ 2)
(A). Sensitivity and specificity of the FibroSURE inflammation score
for a range of cut-off values (B).
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commercially available noninvasive indices of hepatic fi-
brosis and inflammation. FibroSURE is a multicompo-
nent index comprised of six serum markers including
α2-macroglobulin, haptoglobin, apolipoprotein A-1, total
bilirubin, γ-glutamyltransferase, and ALT that are com-
bined with patients’ age and gender to calculate separate
scores for fibrosis and necroinflammatory activity. It iscurrently marketed for liver histology assessment in
chronic HCV-infected patients, and only a few studies
evaluated the utility of this test in chronic HBV infection
[15-20]. However, in all of these studies, as opposed to
performing FibroSURE in a commercial laboratory where
the reproducibility of the test is closely monitored and
subject to performance measures, serum marker measure-
ments in the prior studies were performed in local labora-
tories and calculation of the fibrosis score was performed
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mercially available FibroSURE test has not been evalua-
ted previously in chronic HBV-infected patients from
the United States.
Our data showed that FibroSURE had reasonable ability
to discriminate between HBV-infected patients with mod-
erate to high fibrosis and those with mild or no fibrosis.
Moreover, the performance of FibroSURE test in our
HBV-infected patients was very similar to results previ-
ously published for patients infected with HCV [11]. The
addition of AST and HIV co-infection status to the Fibro-
SURE score significantly improved its discriminatory cap-
acity, with an AUROC of 0.90, making the combination of
these three parameters an excellent index for identifica-
tion of HBV-infected patients with advanced fibrosis. As a
marker of intrahepatic inflammation, FibroSURE showed
good ability to discriminate between patients with mo-
derate to high inflammation and those with mild or no
inflammation. However, its discriminatory ability did not
differ significantly from either ALT or AST individually.
Excellent performance characteristics are only the initial
attribute required for the adaptation in the clinic of any
diagnostic test. In addition, tests must be conveniently
obtainable and readily interpretable in the clinical setting
with a high degree of reproducibility as demonstrated
through laboratory performance characteristics. Reprodu-
cibility is particularly important for serial application of a
test, such as might be required of FibroSURE if it were to
be used as a benchmark for determining treatment
outcome or if it were to be performed repeatedly to assess
progression of inflammation or fibrosis. We [21] and
others [22] have previously shown that the commercially
available FibroSURE has the utility to identify fibrosis pro-
gression in patients with HCV. Whether FibroSURE has
similar prognostic significance in HBV infection remains
to be determined.
A limitation of this study is the small sample size. Al-
though all HBV-infected patients who underwent a liver
biopsy at our institution between 2005 and 2012 were
consecutively approached, their number was small and
not all who were approached agreed to study participa-
tion. However, the racial diversity of our subjects is
representative of the U.S. population of HBV-infected
individuals. In contradistinction to other countries, HBV
infection prevalence in the United States is estimated to
be ~2% among Asians and 0.73% among non-Hispanic
Blacks, the ethnicities with the highest HBV prevalence
in the U.S. [23]. These two groups account for 39% and
31% of individuals, respectively, in the U.S. with chronic
HBV infection. The ethnicity of patients in this study
(40% Asian, 40% Black) is reflective of that found in
the general U.S. population and can be considered a
strength of our study population. An additional limita-
tion of the study is the heterogeneous patient populationconsisting of unequal numbers of HBV mono-infected
and HIV/HBV co-infected patients.
Conclusions
In chronic HBV infection, liver biopsy is usually per-
formed in patients with active disease in order to identify
those who might be expected to benefit the most from
treatment. However, many patients are reluctant to
undergo the procedure due to its invasiveness and high
costs. Our study shows that performance of FibroSURE in
combination with AST levels can be a good substitute for
liver biopsy for estimation of hepatic fibrosis in HBV-
infected patients. The test can be performed on one tube
of blood easily obtained at the point of care. Based upon
these results, we believe that the FibroSURE can be used
to identify patients in whom HBV treatment should be
considered.
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